Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+tumor infiltrating lymphocytes

被引:47
|
作者
Shurell, Elizabeth [1 ]
Singh, Arun S. [2 ,7 ]
Crompton, Joseph G. [1 ]
Jensen, Sarah [2 ]
Li, Yunfeng [3 ]
Dry, Sarah [3 ,7 ]
Nelson, Scott [3 ,7 ]
Chmielowski, Bartosz [2 ,7 ]
Bernthal, Nicholas [4 ,7 ]
Federman, Noah [2 ,7 ]
Tumeh, Paul [5 ,7 ]
Eilber, Fritz C. [1 ,6 ,7 ]
机构
[1] Univ Calif Los Angeles, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Hematol Oncol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Dept Orthopaed Surg, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, Dept Dermatol, Los Angeles, CA 90095 USA
[6] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
[7] UCLA JCCC Sarcoma Program, Los Angeles, CA 90095 USA
关键词
immune microenvironment; MPNST; PD-L1; CD8; sarcoma; SOFT-TISSUE SARCOMA; CHECKPOINT BLOCKADE; UNTREATED MELANOMA; CANCER-THERAPY; BIOMARKERS; IMMUNOTHERAPY; CHEMOTHERAPY; NIVOLUMAB;
D O I
10.18632/oncotarget.11734
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade. Our aim was to evaluate the expression of programmed death-ligand 1 (PD-L1), programmed cell death protein 1 (PD-1), and presence of CD8+ tumor infiltrating lymphocytes (TILs) in MPNST, and correlate these findings with clinical behavior and outcome. Results: PD-L1 staining of at least 1% was seen in 0/20 nerves, 2/68 benign lesions and 9/53 MPNST. Two of 68 benign lesions and 7/53 (13%) MPNST had at least 5% PD-L1 staining. CD8 staining of at least 5% was seen in 1/20 (5%) nerves, 45/68 (66%) benign lesions and 30/53 (57%) MPNST. PD-L1 was statistically more prevalent in MPNST than both nerves and benign lesions (p=0.049 and p=0.008, respectively). Expression of PD-1 was absent in all tissue specimens. There was no correlation of PD-L1 or CD8 expression with disease state (primary versus metastatic) or patient survival. Methods: A comprehensive PNST tissue microarray was created from 141 surgical specimens including primary, recurrent, and metastatic MPNST (n=53), neurofibromas (n=57), schwannoma (n=11), and normal nerve (n=20). Cores were stained in triplicate for PD-L1, PD-1, and CD8, and expression compared between tumor types. These data were then examined for survival correlates in 35 patients with primary MPNST. Conclusions: MPNST is characterized by low PD-L1 and absent PD-1 expression with significant CD8+ TIL presence. MPNST immune microenvironment does not correlate with patient outcome.
引用
收藏
页码:64300 / 64308
页数:9
相关论文
共 50 条
  • [41] Malignant Phyllodes Tumors Express PD-L1 Independent of Degree of Tumor Infiltrating Lymphocytes
    Barrett, Amanda
    Taube, Janis
    Argani, Pedram
    Emens, Leisha
    Cimino-Mathews, Ashley
    LABORATORY INVESTIGATION, 2018, 98 : 49 - 49
  • [42] Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
    Koirala, Pratistha
    Roth, Michael E.
    Gill, Jonathan
    Piperdi, Sajida
    Chinai, Jordan M.
    Geller, David S.
    Hoang, Bang H.
    Park, Amy
    Fremed, Michael A.
    Zang, Xingxing
    Gorlick, Richard
    SCIENTIFIC REPORTS, 2016, 6
  • [43] Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
    Koirala, Pratistha
    Roth, Michael
    Gill, Jonathan
    Chinai, Jordan
    Piperdi, Sajida
    Geller, David
    Hoang, Bang
    Poon, Vincent
    Zang, Xingxing
    Gorlick, Richard
    CANCER RESEARCH, 2016, 76
  • [44] Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas
    Lucie Duverger
    Amélie Osio
    Bernard Cribier
    Laurent Mortier
    Adèle De Masson
    Nicole Basset-Seguin
    Céleste Lebbé
    Maxime Battistella
    Cancer Immunology, Immunotherapy, 2019, 68 : 951 - 960
  • [45] Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma
    Garcia-Marin, Rocio
    Reda, Sara
    Riobello, Cristina
    Cabal, Virginia N.
    Suarez-Fernandez, Laura
    Vivanco, Blanca
    Alvarez-Marcos, Cesar
    Lopez, Fernando
    Llorente, Jose L.
    Hermsen, Mario A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [46] Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas
    Duverger, Lucie
    Osio, Amelie
    Cribier, Bernard
    Mortier, Laurent
    De Masson, Adele
    Basset-Seguin, Nicole
    Lebbe, Celeste
    Battistella, Maxime
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (06) : 951 - 960
  • [47] Combined Classification of PD-L1 Expression and CD8+Tumor Infiltrating Lymphocytes (CD8+TIL) As a Predictor of Prognosis in Ovarian High Grade Serous Carcinoma (HGSC): A Clinicopathologic Study with Molecular Correlation
    Wu, Daisy
    Aggarwal, Arpit
    Menghi, Francesca
    Corbin, Haley
    Banda, Kalyan
    Rodriguez, Isabel
    Radke, Marc
    Liu, Edison
    Madabhushi, Anant
    Swisher, Elizabeth
    Soong, T. Rinda
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1269 - S1270
  • [48] CD274/PD-L1 copy number gained malignant peripheral nerve sheath tumor: A case report and literature review
    Na, Kiyong
    Kim, Hong Jun
    MEDICINE, 2025, 104 (01)
  • [49] Patterns of PD-L1 expression and tumor infiltrating immune cells in resected NSCLC
    Gureviciene, Giedre
    Matulione, Jurgita
    Poskiene, Lina
    Miliauskas, Skaidrius
    Zemaitis, Marius
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [50] Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment
    Sajjad Gerdabi
    Fatemeh Asadian
    Razie Kiani
    Bijan Khademi
    Mohammad Reza Haghshenas
    Nasrollah Erfani
    Head and Neck Pathology, 2023, 17 : 178 - 192